[{"id":"2770c644-c8c6-4b54-8f58-0b1d8f8f4795","acronym":"IO-202-CL-001","url":"https://clinicaltrials.gov/study/NCT04372433","created_at":"2023-05-17T22:04:43.287Z","updated_at":"2025-02-25T14:40:35.488Z","phase":"Phase 1","brief_title":"IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML","source_id_and_acronym":"NCT04372433 - IO-202-CL-001","lead_sponsor":"Immune-Onc Therapeutics","biomarkers":" LILRB4","pipe":"","alterations":" ","tags":["LILRB4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • IO-202"],"overall_status":"Completed","enrollment":" Enrollment 67","initiation":"Initiation: 09/14/2020","start_date":" 09/14/2020","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 01/31/2025","study_completion_date":" 01/31/2025","last_update_posted":"2025-02-14"},{"id":"4fa2d9d4-6a40-43ec-bdcf-d1701a41dac8","acronym":"","url":"https://clinicaltrials.gov/study/NCT05309187","created_at":"2024-06-08T04:16:43.361Z","updated_at":"2024-07-02T16:34:58.981Z","phase":"Phase 1","brief_title":"Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid Tumors","source_id_and_acronym":"NCT05309187","lead_sponsor":"Immune-Onc Therapeutics","biomarkers":" LILRB4","pipe":"","alterations":" ","tags":["LILRB4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • IO-202"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 04/11/2022","start_date":" 04/11/2022","primary_txt":" Primary completion: 03/29/2024","primary_completion_date":" 03/29/2024","study_txt":" Completion: 05/31/2024","study_completion_date":" 05/31/2024","last_update_posted":"2024-06-04"},{"id":"ce6acbdf-d0c9-46e4-a247-444e713619ba","acronym":"","url":"https://clinicaltrials.gov/study/NCT06413095","created_at":"2024-05-18T04:21:47.057Z","updated_at":"2025-02-25T16:02:48.188Z","phase":"Phase 1","brief_title":"PBI-MST-01 (NCT04541108) Substudy MSD-03: Intratumoral Microdosing of Pembrolizumab Alone and With MK-0482 or MK-4830 in HNSCC or STS","source_id_and_acronym":"NCT06413095","lead_sponsor":"Presage Biosciences","biomarkers":" CD8 • IFNG • CD163 • GZMB","pipe":"","alterations":" ","tags":["CD8 • IFNG • CD163 • GZMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • MK-0482 • MK-4830"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 06/01/2022","start_date":" 06/01/2022","primary_txt":" Primary completion: 06/22/2023","primary_completion_date":" 06/22/2023","study_txt":" Completion: 06/22/2023","study_completion_date":" 06/22/2023","last_update_posted":"2024-05-14"},{"id":"569b7a3c-398d-4a63-9bd9-f84589797a41","acronym":"","url":"https://clinicaltrials.gov/study/NCT03918278","created_at":"2021-03-22T14:52:14.407Z","updated_at":"2024-07-02T16:35:15.378Z","phase":"Phase 1","brief_title":"A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001)","source_id_and_acronym":"NCT03918278","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" EGFR • ALK • ROS1 • MGMT","pipe":" | ","alterations":" IDH wild-type","tags":["EGFR • ALK • ROS1 • MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • gemcitabine • albumin-bound paclitaxel • pemetrexed • MK-0482"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 230","initiation":"Initiation: 06/19/2019","start_date":" 06/19/2019","primary_txt":" Primary completion: 02/19/2025","primary_completion_date":" 02/19/2025","study_txt":" Completion: 02/19/2025","study_completion_date":" 02/19/2025","last_update_posted":"2024-03-11"},{"id":"e7bd79ed-e1db-4e9b-bb76-4a8a179e7ded","acronym":"","url":"https://clinicaltrials.gov/study/NCT05913804","created_at":"2023-06-22T19:11:41.291Z","updated_at":"2024-07-02T16:35:45.048Z","phase":"Phase 1","brief_title":"YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple Myeloma","source_id_and_acronym":"NCT05913804","lead_sponsor":"Institute of Hematology \u0026 Blood Diseases Hospital","biomarkers":" LILRB4","pipe":"","alterations":" ","tags":["LILRB4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • YTS104"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 8","initiation":"Initiation: 06/15/2023","start_date":" 06/15/2023","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2023-06-22"},{"id":"893364f9-94b4-4ba6-a42f-b2399b5cc9bc","acronym":"","url":"https://clinicaltrials.gov/study/NCT05739409","created_at":"2023-05-17T22:04:44.533Z","updated_at":"2024-07-02T16:35:55.011Z","phase":"","brief_title":"LILRB4 STAR-T Cell Therapy for Monocytic Leukemia","source_id_and_acronym":"NCT05739409","lead_sponsor":"Institute of Hematology \u0026 Blood Diseases Hospital","biomarkers":" LILRB4","pipe":"","alterations":" ","tags":["LILRB4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • YTS104"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 02/01/2023","start_date":" 02/01/2023","primary_txt":" Primary completion: 02/01/2024","primary_completion_date":" 02/01/2024","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2023-02-22"},{"id":"e88da068-9605-4405-b63c-5767e31d20f7","acronym":"","url":"https://clinicaltrials.gov/study/NCT05518357","created_at":"2023-05-17T22:04:43.826Z","updated_at":"2024-07-02T16:35:57.735Z","phase":"Phase 1","brief_title":"LILRB4 STAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT05518357","lead_sponsor":"Hebei Yanda Ludaopei Hospital","biomarkers":" LILRB4","pipe":"","alterations":" ","tags":["LILRB4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • YTS104"],"overall_status":"Completed","enrollment":" Enrollment 2","initiation":"Initiation: 06/24/2022","start_date":" 06/24/2022","primary_txt":" Primary completion: 11/15/2022","primary_completion_date":" 11/15/2022","study_txt":" Completion: 11/15/2022","study_completion_date":" 11/15/2022","last_update_posted":"2023-01-12"},{"id":"de59778c-3ed1-4ae8-9ba9-f43ec335a40c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05548088","created_at":"2023-05-17T22:04:44.026Z","updated_at":"2024-07-02T16:36:03.673Z","phase":"Phase 1","brief_title":"LILRB4 STAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT05548088","lead_sponsor":"Peking University People's Hospital","biomarkers":" LILRB4","pipe":"","alterations":" ","tags":["LILRB4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • YTS104"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 11/30/2022","start_date":" 11/30/2022","primary_txt":" Primary completion: 12/30/2023","primary_completion_date":" 12/30/2023","study_txt":" Completion: 08/30/2024","study_completion_date":" 08/30/2024","last_update_posted":"2022-09-21"}]